Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Aneurysmal Subarachnoid Hemorrhage (aSAH)
Clinical Trial
NCT05995405Last updated: 12/4/2025
GRCE
Grace Therapeutics, Inc.